ADCs have to carry enough drug to kill cancer cells, get inside the target cell, and only then release the drug.

Antibody-Drug Conjugates Stage a Comeback

ADC developers have had to overcome some significant technical challenges to produce molecules that begin to fulfill the promise of this approach to cancer treatment. Of the total antibodies in clinical trials, the percentage of these immunoconjugates decreased from 56% to 49% to 31% in the 1980s, 1990s, and 2000–2005, respectively. The numbers suggest that while the advantages of ADCs are obvious, the technology had not yet fully arrived. In the last five years, however, there has been a surge of technical advances that is beginning to push these candidates through development.

... Full Report

• GEN Print
  SUBSCRIBE NOW! Renew / Update (US only)
• e-Newsletters
  View / Sign Up
• RSS
  View Feeds

visit the Career Center

• GEN Webinars: Implementing a Successful Process Analytical Technology Strategy
• (Available for On-Demand viewing)
• In this webinar you will learn about the importance of choosing and implementing forward-looking tec ...learn more.

• Mar 30 2010
• High-Content Protein Microarrays for Biomarker Discovery and Therapeutic Response Monitoring
• Invitrogen
• Mar 25 2010
• Advanced Platforms for Discovery and Validation of Protein Therapeutics
• Invitrogen
• Mar 23 2010
• Multi-milligram to Gram Scale Protein Production in Mammalian Cells in 5 Days
• Invitrogen
• Mar 16 2010
• The Search for a True Identity : Defining Characteristics of Bona Fide Human iPS Cells
• Stemcell Technologies

view all webinars

ADVERTISEMENT

• Listen
• Save
• Comment
• View All

INTERVIEW: WATER-WISE PLANTS FOR A WORLD GROWING WARMER - Interview with Julian Schroeder, Ph.D., Professor of Biology, University of California, San Diego ...MORE

ADVERTISEMENT